Elicio Therapeutics Hosts Expert Event on ELI-002 7P for Pancreatic Cancer

PUBT · 19h ago
Elicio Therapeutics Hosts Expert Event on ELI-002 7P for Pancreatic Cancer
  • Elicio Therapeutics will host a virtual key opinion leader event on November 11, 2026, at 2:30 p.m. ET.
  • Discussions will cover Phase 2 findings guiding camupepimut's (ELI-002 7P) late-stage development for metastatic pancreatic cancer.
  • Speakers will also address neoadjuvant pancreatic cancer opportunities, including the ongoing Memorial Sloan Kettering-led Phase 1 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040800PRIMZONEFULLFEED9869073) on November 04, 2026, and is solely responsible for the information contained therein.